| Literature DB >> 34470608 |
Joanna Kruk1, Basil Hassan Aboul-Enein2, Ewa Duchnik3.
Abstract
Melatonin possesses the indoleamine structure and exerts antioxidant and anti-inflammatory actions and other physiological properties. Physical exercise can influence secretion of melatonin. Melatonin is used as a natural supplement among athletes to regulate sleep cycles and protect muscles against oxidative damage. Despite decades of research, there is still a lack of a comprehensive and critical review on melatonin supplementation and physical activity relationship. The aim of this literature review is to examine the antioxidant, anti-inflammatory and other biological functions played by melatonin with reference to the effect of physical exercise on melatonin secretion and the effect of this compound supplementation on exercise-induced oxidative stress in athletes. Evidence shows that intense exercises disturb antioxidant status of competitive athletes, whereas supplementation with melatonin strengthens antioxidant status in trained athletes in various sports as the compound showed high potency in reduction of the oxidative stress and inflammation markers generated during intense and prolonged exercise.Entities:
Keywords: Bioactivity; Exercise; Inflammation; Melatonin; Oxidative stress; Supplementation
Mesh:
Substances:
Year: 2021 PMID: 34470608 PMCID: PMC8409271 DOI: 10.1186/s12576-021-00812-2
Source DB: PubMed Journal: J Physiol Sci ISSN: 1880-6546 Impact factor: 2.781
Fig. 1Chemical structures of melatonin (MT) and its main metabolites: 3-OHMT (3-hydroxymelatonin); 6-OHMT (6-hydroxymelatonin); AMK (N1-acetyl-5-metoxyknuramine); AFMK (N1-acetyl-N2-formyl-5-metoksyknuramine)
Fig. 2Simplified scheme for the biological functions performed by melatonin
The effect of physical exercise on melatonin levels in humans
| Study, year | Participant characteristics | Category, timing of PE and MT detection | Main results | Author’s conclusion |
|---|---|---|---|---|
| Thrift et al. 2014 [ | RCT (51 men, 49 women and 51 men and 51 women as a stretching control (average age 40–75 years, previously sedentary) | 12-month program of moderate-to-vigorous exercise (60 min daily, 6 days/week at 60–80% MT detection: baseline and 12-month follow-up urinary metabolite of MT, 6-sulphatoxymelatonin | No statistically significant changed concentrations of 6-sulphatoxymelatonin after 12-months exercises vs controls (p = 0.66). Baseline metabolite levels were significantly higher in women compared to men, but not after exercise | Moderate-to-vigorous 12-month exercise did not change level of 6-sulphatoxymelatonin |
| Kilic et al. 2016 [ | Ten healthy, sedentary males (average age 22.2 ± 0.24 years) | Strenuous exercise as acute exercise until exhaustion, according to the Bruce protocol (Cosmed T150 treadmill test). Blood MT detection at rest, at 10:00 a.m. and immediately after exercise as well as after 48 h at 12.00 p.m. (rest) and immediately after exercise | No statistically significant change in serum MT levels after exercise performed during day or night vs the levels at rest: (3.63 ± 0.08 vs 3.37 ± 0.18 and 4.41 ± 0.26 vs 4.33 ± 0.21, pg/mL, respectively) | Exhaustion PE did not affect the level of MT in the blood, independently on exercise timing (daytime, at night) |
| Zarei et al. 2016 [ | Thirteen healthy, non-athletic males (average age 19–23 years) | 20 min daily of moderate-intensity exercise (running, 50–60% MT measurements: 24 h prior to exercise, 48 h after exercise, two months after the last exercise | Significantly decreased MT levels in PBMCs with exercise: post-exercise 7.94 ± 0.35 pg/mL, 2-month silent 6.05 ± 0.27 pg/mL vs pre-exercise (9.16 ± 0.19 pg/mL). Significantly increased IL-17 secretion by 39% in the post-exercise time | Long-lasting engaging in moderate-intensity exercise caused decrease in MT release, and increase in IL-17 cytokine level |
| De Aquino Lemos et al. 2018 [ | RCT ( normoxia ( | Aerobic moderate exercise on a treadmill at 50% of VT1 for 60 min, performed under normoxia and hypoxia conditions from 11:00 a.m. to 12:00 noon blood MT detection: at 7:30 a.m. (the 1st and 2nd days), at 10:30 p.m. (the 1st and 2nd nights) | Significantly increased nocturnal blood MT levels in the hypoxia group vs the normoxia group after the second night; both values were lower than those in the exercise group under hypoxia | PE under hypoxia enhances nocturnal level of MT, influences its daytime level, and improves sleep quality |
| Carlson et al. 2019 [ | 12 healthy males, regularly exercising, runnerslage (average age 20.7 ± 0.62 years) | Three protocols: 30 min of steady state running on a level treadmill at 75% | Significantly increased levels of MT at 03:00 a.m. compared with those at 8:00 and 10:00 p.m. after completed all the protocol session. MT level at 10.00 p.m. was significantly, elevated (by 20%) after morning exercise vs afternoon exercise | Exercising in the morning may increase MT release compared with exercise performed at afternoon |
| O’Donnell et al. 2019 [ | Ten elite female netball athletes (average age 23 ± 6 years) | Athletes one netball training session over a 7-day period and one rest day (control). Mean heart rate during training—145 ± 10 bpm, mean rating of perceived exertion—14 ± 1 according to the Borg scale MT detection: immediately pre-training, 7:15 p.m. and post-training 10:00 p.m. and during control day | Significantly decreased salivary MT levels in pre-training (6.2 pg/mL) and post-training (17.6 pg/mL) vs a rest day (14.8 and 24.3 pg/mL), respectively) | Training caused significantly decreased levels of MT |
MT melatonin, PE physical exercise, PBMCs peripheral blood monocular cells, RCT randomized controlled trial
Characteristics of the representative epidemiological studies on the effect of melatonin supplementation on exercise-induced oxidative stress in humans
| Study, year | Participant characteristics | MT supplementation | Exercise measured | Results | Conclusions |
|---|---|---|---|---|---|
| Ochoa et al. 2011 [ | Highly trained performing regular exercise amateur athletes ( | Oral intake of five tablets of 3 mg MT: one tablet two days before the exercise test, three tablets on the previous days and one tablet 1 h before beginning the test | High intensity constant run with several degrees of high effort on total distance 50 km with permanent climbing, altitude changing from 640 to 3393 m | Significantly increased blood levels of TNF-α, IL-6, IL-1Ra, urine 8-OHdG and isoprostane concentrations in both tested groups. Efficiently reduced lipid peroxides, TNF-α and 8-OHdG before and after exercise in the MT group vs placebo group | MT supplementation can reduce muscle damage via modulation of OS and preventing overexpression of proinflammatory cytokines |
| Maldonado et al. 2012 [ | 16 young male football players (experimental group | Experimental group treated with 6 mg MT, control group treated with placebo, 30 min prior to exercise | Acute sport training of high intensity (heart rate 135 beats per minute) | Exercise increased MDA in both groups, but significantly decreased in MT group after 60 min of training. Decreased triglyceride and increased serum IgA levels after training in MT group | Supplementation with MT in acute sport training decreased the OS generated by exercise, enhanced the serum TAS, and improved metabolism of lipids |
| Leonardo-Mendonça et al. 2017 [ | Randomized double-blind study of 24 resistance trained students (males). MT-treated men | Experimental group supplemented with MT (100 mg daily, 30 min before bedtime for 4 weeks) | 8 sessions a week (about 10 h/week): 5 sessions-resistance training (3 sessions between 60–75% of maximal strength and 2 sessions between 80 and 90% of maximal strength), 2 sessions—weight training and 1 session—aerobic running | Increased ORAC levels by MT vs placebo after exercise. Reduced LPO, iNOS, GSSG/GSH and GPx/GRd ratios, CK, LDH, creatinine, cholesterol. Prevention against AOPP increase in MT group vs placebo group | MT enhanced potency of the endogenous antioxidant system, restored redox equilibrium state and protected against OS damage |
| Ortiz-Franco et al. 2017 [ | 14 male healthy athletes (age: 20–37 years) engaged in a 2-week randomized, double-blinded trial (MT-treated group and placebo-treated group) | 20 mg MT/day or placebo administered before exercise during the controlled study period (MT group) | Training program combined strength and high intensity interval trainings (6 sessions/week 60–75 min/day. | Significantly increased MT level, TAC and GPx levels, decreased DNA damage in MT-treated group vs placebo group after 2-week exercise | MT treatment strengthens antioxidant state of athletes and protects DNA from damage caused by high intensity exercise |
| Ziaadini et al. 2017 [ | Two groups of sedentary women: involved in exercise training and treated with MT ( | 3 mg/day MT supplementation before exercise training | 8-week (3 days/week) exercise training of increasing intensity and volume from 60 to 80% HRmax through 15 to 45 min | Significantly increased levels of MDA after long-lasting aerobic exercise training. Suppression of post-exercise increased MDA in the exercising and supplemented group | Supplementation with MT may decrease ROS levels, thus improve lipid profile |
| Beck et al. 2018 [ | 11 males moderately active, mean age: 24.18 ± 3.92 years | MT (6 mg) or placebo ingestion 30 min before exercise | Exercise on cycloergometer with initial workloads of 75 W and increments of 15 W each 3 min till exhaustion Maximal aerobic capacity 120.88 ± 18.78 W | A time to exhaustion significantly lower in placebo group compared to that with MT administered by approximately 19% | MT supplementation enhanced aerobic tolerance but was without effect on the biochemical and hematological parameters |
| Brandenberger et al. 2018 [ | Ten cyclists long-distance training, mean age 25.0 ± 4.0 years | 5 mg MT administered 15 min before time trial. Controls: placebo 15 min before time trial | 32.2 km cycling time trial performance at | No statistically significant differences between both groups in duration (completion times: MT group 64.94 ± 5.95 min, placebo group 65.26 ± 6.85) | Supplementation of MT did not exhibit of significant effect on performance in thermoneutral environment |
| Czuczejko et al. 2019 [ | Professional athletes: 47 football players, 19 rowers, 15 adults non-training males (control group) | 5 mg MT administered before sleep through 30 days in the preparatory period for athlete’s competition | Athletes: exercise on a cycle ergometer at 75% | Decreased blood MT levels in footballers and rowers vs controls before MT intake. Increased serum MT level in footballers and in rowers after a 30-day MT intake. Reduced OS markers: MDA, IL-6, CRP, and low-density lipoproteins | Supplementation of MT in professional athletes during intense training may protect against the toxic action of ROS/RNS and inflammation |
| Souissi et al. 2018 [ | Eight healthy moderately trained male students, mean age: 21.8 ± 0.9 years | 6 mg MT supplementation or placebo at 09:00 a.m. in a randomized order 50 min before exercise | Running at 60% | Exercise elevated inflammatory markers: CRP, LDH, ALAT, ASAT in both placebo or MT intake groups | MT ingestion before moderate prolonged submaximal exercise showed no anti-inflammatory action |
| Cheikh et al. 2020 [ | Randomized double-blind trial of 14 healthy-trained male athletes, mean age 154 ± 0.3 years | 10 mg MT or placebo ingestion (control) after vigorous late-evening exercise (10:00 p.m.) | Two-test sessions (separated at least one week) Running-Based Anaerobic Sprint Test at 8:00 p.m. and in the following morning (7:30 a.m.) | Reductions of: WBC, NE, LY, CRP, muscle and hepatic damage enzymes (CK, ASAD), LDH, MDA and homocysteine before and after strenuous exercise vs placebo group | MT intake after strenuous late-evening exercise diminished transient leukocytosis and protected against lipid peroxidation and muscle damage in teenage athletes |
| Farjallach et al. 2019 [ | 20 soccer players mean age 18.81 ± 1.3 years, MT group ( | Nocturnal oral MT (5 mg) or placebo ingestion in a double-blind manner | Intensive 6-day training-repeated sprint ability test: sprints 6 × 40 m with a 20 s of passive recovery between repetitions | Decreased resting OS markers: AOPP, leukocytosis and CK. Decreased post-exercise leukocytosis and markers of cellular damage (CK, ASAT, ALAT), increased GPx and GR activities in MT-treated group vs placebo group | Nocturnal MT intake during intensive training decreased OS, leukocytosis, cellular damage, and improved exercise performance |
LY lymphocytes, WBC white blood cells, NE neutrophils, CRP C-reactive protein, CK creatine kinase, LDH lactate dehydrogenase, ASAT aspartate aminotransferase, MDA malonaldehyde, LDL low-density lipoprotein, maximal oxygen uptake, ALAT alanine aminotransferase, CHO formaldehyde, ORAC oxygen radical absorption capacity, LPO lipid peroxidation, GSH glutathione, GSSG glutathione disulphide, AOPP advanced oxidation proteins products, MT melatonin, GPx glutathione peroxidase, GR glutathione reductase, TAC antioxidant status, iNOS inducible nitric oxide synthase, IL-1Ra, interleukin-1 receptor antagonist, 8-OHdG 8-hydroxy-2′-deoxyguanosine